MicroRNA‑125a‑5p inhibits invasion and metastasis of gastric cancer cells by targeting BRMS1 expression

Cao, Yi; Tan, Shengxing; Tu, Yi; Zhang, Guoyang; Liu, Yi; Li, Daojiang; Xu, Shan; Le, Zhibiao; Xiong, Jianbo; Zou, Wenyu; Gong, Peitao; Li, Zhengrong; Jie, Zhigang

doi:10.3892/ol.2018.7983

Cited by 27 publications

(33 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9D). To confirm the above conclusion, miR-125a-5p inhibitors were synthesized and transfected into GES-1 cells, which exhibit high levels of miR-125a-5p expression 22 and low levels of FOXS1 expression. The RT-PCR results showed that the expression of miR-125a-5p was inhibited after transfection with miR-125a-5p inhibitors, with no change in the mRNA levels of FOXS1 (Fig.…”

Section: Resultsmentioning

confidence: 84%

FOXS1 is regulated by GLI1 and miR-125a-5p and promotes cell proliferation and EMT in gastric cancer

Wang

Ran

Zhang

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Gastric cancer (GC) is the fourth most common malignant neoplasm and the second leading cause of cancer death. Identification of key molecular signaling pathways involved in gastric carcinogenesis and progression facilitates early GC diagnosis and the development of targeted therapies for advanced GC patients. Emerging evidence has revealed a close correlation between forkhead box (FOX) proteins and cancer development. However, the prognostic significance of forkhead box S1 (FOXS1) in patients with GC and the function of FOXS1 in GC progression remain undefined. In this study, we found that upregulation of FOXS1 was frequently detected in GC tissues and strongly correlated with an aggressive phenotype and poor prognosis. Functional assays confirmed that FOXS1 knockdown suppressed cell proliferation and colony numbers, with induction of cell arrest in the G0/G1 phase of the cell cycle, whereas forced expression of FOXS1 had the opposite effect. Additionally, forced expression of FOXS1 accelerated tumor growth in vivo and increased cell migration and invasion through promoting epithelial–mesenchymal transition (EMT) both in vitro and in vivo . Mechanistically, the core promoter region of FOXS1 was identified at nucleotides −660~ +1, and NFKB1 indirectly bind the motif on FOXS1 promoters and inhibit FOXS1 expression. Gene set enrichment analysis revealed that the FOXS1 gene was most abundantly enriched in the hedgehog signaling pathway and that GLI1 expression was significantly correlated with FOXS1 expression in GC. GLI1 directly bound to the promoter motif of FOXS1 and significantly decreased FOXS1 expression. Finally, we found that miR-125a-5p repressed FOXS1 expression at the translational level by binding to the 3′ untranslated region (UTR) of FOXS1. Together, these results suggest that FOXS1 can promote GC development and could be exploited as a diagnostic and prognostic biomarker for GC.

show abstract

Section: Resultsmentioning

confidence: 84%

FOXS1 is regulated by GLI1 and miR-125a-5p and promotes cell proliferation and EMT in gastric cancer

Wang

Ran

Zhang

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In this study, we observed the expression of miR-125a-5p and miR-141-3p, largely because previous studies have reported that these have a relatively clear correlation with cancer. It is reported that the decrease of miR-125a-5p expression in gastric cancer is closely related to tumorigenesis and poor prognosis [16], and miR-125a-5p can inhibit the invasion and migration of hepatic cancer cells by regulating the activity of the PI3K/AKT/mTOR pathway [17].On the other hands, high levels of miR-141-3p expression have been reported to target PTEN, which in turn leads to activation of the PI3K-Akt pathway [18]. In this study, the expression levels of exosomal miR-141-5p and miR-125a-5p, as well as the miR-141-5p/miR-125a-5p ratio, were determined.…”

Section: Discussionmentioning

confidence: 99%

Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer

Li¹,

Dong²,

Wang³

et al. 2021

neo

View full text Add to dashboard Cite

Predictive biomarkers for early diagnosis of prostate cancer are important for its treatment. The functional microRNAs in the exosomes of plasma and serum samples are of interest as stable and non-invasive biomarkers for recurrence in cancer patients. The present study aimed to clarify the value of plasma exosomal mRNA-125a-5p and miR-141-5p miRNAs as biomarkers for the diagnosis of prostate cancer. The study included 19 healthy individuals and 31 prostate cancer patients. In comparison to the levels in healthy controls, exosomal miR-141-5p levels showed a slight increase in prostate cancer patients (P = 0.085), and miR-125a-5p levels that showed a significant decrease in patients with prostate cancer than in healthy controls (P = 0.032). As a derived parameter, the miR-125a-5p/miR-141-5p ratio was significantly higher in patients with prostate cancer than in healthy controls (P < 0.001). We found that exosomal miR-141-5p in plasma showed a promise in distinguishing prostate cancer patients with the AUC was 0.652, and for miR-125a-5p, the AUC was 0.691. For the miR-125a-5p/miR-141-5p ratio, the AUC value was 0.793. We found that miR-125a-5p has a weak positive correlation with PSA (correlation coefficient = 0.3413). Moreover, miR-141-5p has been found to hold a negatively no-significant correlation with PSA, with the correlation coefficient is-0.1102. We speculate that, as diagnostic markers for prostate cancer, miR-125-5p and miR-141-5p might be independent of the PSA. In summary, the results of this study suggest that high plasma exosomal expression of miR-141-3p and low expression of miR-125a-5p in plasma exosomes from prostate cancer patients might be useful markers of specific tumor traits associated with prostate cancer. Moreover, the miR-125a-5p/miR-141-5p ratio seems to perform better than either of the single values alone.

show abstract

“…Since TRIM7 also promoted the ubiquitination of BRMS1, these studies suggest that TRIM7 and BRMS1 may closely interact with each other in osteosarcoma cells. BRMS1 was first found in breast cancer, and its anti-metastasis functions were also confirmed in other cancers such as osteosarcoma, prostate, gastric and lung cancer [15] , [16] , [17] , [18] , where lower expression of BRMS1 was associated with increased cancer cell metastasis. Additionally, knockdown of BRMS1 displays mesenchymal characteristics and enhances cell invasion and migration, along with decreased E-cadherin and increased Vimentin and Twist1 [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1

Zhou

Zhang

Zhu³

et al. 2020

eBioMedicine

View full text Add to dashboard Cite

Background Metastasis is the leading cause of death in patients with osteosarcoma. Some of these patients fail to respond to chemotherapy and die of metastasis within a short period. Therefore, it is important to identify novel biomarkers to improve the diagnosis and treatment of osteosarcoma. TRIM7 is a member of the tripartite motif (TRIM) family protein that is involved in various pathological conditions including cancer; however, its role in osteosarcoma remains elusive. Methods Cell proliferation, invasion and migration were measured by CCK-8 and Transwell. Immunoprecipitation and mass spectrometry analysis were used to identify candidate proteins associated with TRIM7. Immunoprecipitation, immunofluorescence, pull down and ubiquitination assay were performed to examine the regulation between TRIM7 and its candidate protein. m6A modification of TRIM7 was measured by RNA immunoprecipitation. Findings TRIM7 expression was upregulated in osteosarcoma tissues and was an independent risk factor in predicting poor prognosis. TRIM7 regulates osteosarcoma cell migration and invasion through ubiquitination of breast cancer metastasis suppressor 1 (BRMS1). Moreover, chemoresistance was readily observed in osteosarcoma cells and in patient-derived xenograft (PDX) mice with higher TRIM7 levels. Loss of TRIM7 m6A modification was observed in osteosarcoma tissues. METTL3 and YTHDF2 were the main factors involved in the aberrant m6A modification of TRIM7. Interpretation Overall, our findings show that TRIM7 plays a key role in regulating metastasis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. Funding This work was financially supported by grants of NSFC (81001192, 81672658 and 81972521) and National Key Research Project of Science and Technology Ministry (2016YFC0106204).

show abstract

MicroRNA‑125a‑5p inhibits invasion and metastasis of gastric cancer cells by targeting BRMS1 expression

Cited by 27 publications

References 43 publications

FOXS1 is regulated by GLI1 and miR-125a-5p and promotes cell proliferation and EMT in gastric cancer

FOXS1 is regulated by GLI1 and miR-125a-5p and promotes cell proliferation and EMT in gastric cancer

Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer

N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1

Contact Info

Product

Resources

About